PPARα and PPARγ dual agonists for the treatment of type 2 diabetes and the metabolic syndrome

Current Opinion in Pharmacology

Volumn 6, Issue 6, 2006, Pages 606-614

  Fiévet, Catherine ^a,b,c   Fruchart, Jean Charles ^a,b,c   Staels, Bart ^a,b,c  

^a INSTITUT PASTEUR DE LILLE   (France)

^b INSERM   (France)

^c UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; FARGLITAZAR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLUCOSE; IMIGLITAZAR; INSULIN; LIGAND; LIPID; METAGLIDASEN; METFORMIN; MIFOBATE; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PIOGLITAZONE; PLACEBO; RAGAGLITAZAR; ROSIGLITAZONE; SULFONYLUREA; TESAGLITAZAR; UNCLASSIFIED DRUG; UNINDEXED DRUG; 2 ETHOXY 3 (4 ((4 (METHYLSULFONYLOXY)PHENETHYL)OXY)PHENYL)PROPANOIC ACID; 2-ETHOXY-3-(4-((4-(METHYLSULFONYLOXY)PHENETHYL)OXY)PHENYL)PROPANOIC ACID; ALKANESULFONIC ACID; DRUG DERIVATIVE; GLYCINE; OXAZOLE DERIVATIVE; PHENYLPROPIONIC ACID DERIVATIVE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; ANGIOSARCOMA; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIET THERAPY; DRUG ACTIVITY; DRUG BINDING; DRUG CARCINOGENICITY; DRUG CROSS REACTIVITY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; FLUID RETENTION; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; KIDNEY DYSFUNCTION; LEUKOPENIA; LIPID METABOLISM; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; STROKE; TRANSIENT ISCHEMIC ATTACK; WEIGHT GAIN; ANIMAL; BIOLOGICAL MODEL; DRUG POTENTIATION;

ALKANESULFONATES; ANIMALS; DIABETES MELLITUS, TYPE 2; GLYCINE; HUMANS; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OXAZOLES; PHENYLPROPIONATES; PPAR ALPHA; PPAR GAMMA;

EID: 33750511973     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.06.009     Document Type: Review

References (48)

1. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
2. No authors listed: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) Group. Lancet 1998, 352:837-853.
3. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., and Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
4. Erkelens D.W. Insulin resistance syndrome and type 2 diabetes mellitus. Am J Cardiol 88 (2001) 38J-42J
5. Berger J.P., Akiyama T.E., and Meinke P.T. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 26 (2005) 244-251
6. Robins S.J., Rubins H.B., Faas F.H., Schaefer E.J., Elam M.B., Anderson J.W., and Collins D. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
7. Keech A., Simes R.J., Barter P., Best J., Scott R., Taskinen M.R., Forder P., Pillai A., Davis T., Glasziou P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
8. Dormandy J.A., Charbonnel B., Eckland D.J., Erdmann E., Massi-Benedetti M., Moules I.K., Skene A.M., Tan M.H., Lefebvre P.J., Murray G.D., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
9. Duez H., Lefebvre B., Poulain P., Torra I.P., Percevault F., Luc G., Peters J.M., Gonzalez F.J., Gineste R., Helleboid S., et al. Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation. Arterioscler Thromb Vasc Biol 25 (2005) 585-591. Testing the effects of two different PPARα agonists - fenofibrate and gemfibrozil - on HDL and apoAI, the authors show that, owing to a differential recruitment of coactivators to the promoters, fenofibrate behaves as a full agonist and enhances apoAI gene transcription, whereas gemfibrozil acts as a partial agonist without effect on apoAI gene expression. Moreover, this study demonstrates that PPARα expression levels determine the response to fibrates.
10. Camp H.S., Li O., Wise S.C., Hong Y.H., Frankowski C.L., Shen X., Vanbogelen R., and Leff T. Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes 49 (2000) 539-547
11. Burgermeister E., Schnoebelen A., Flament A., Benz J., Stihle M., Gsell B., Rufer A., Ruf A., Kuhn B., Marki H.P., et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol 20 (2006) 809-830. The authors identify a novel PPARγ partial agonist, the isoquinoline derivative PA-082, in terms of its biochemical properties, binding mode and cellular effects. They propose that selective recruitment of PPARγ coactivator-α to favourable PPARγ-target genes provides a possible molecular mechanism whereby partial PPARγ agonists dissociate TG accumulation from insulin signalling (SPPARγM effect).
12. Lalloyer F., Vandewalle B., Percevault F., Torpier G., Kerr-Conte J., Oosterveer M., Paumelle R., Fruchart J., Kuipers F., Pattou F., et al. PPARalpha improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 55 (2006) 1605-1613
13. Ravnskjaer K., Boergesen M., Rubi B., Larsen J.K., Nielsen T., Fridriksson J., Maechler P., and Mandrup S. Peroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cells. Endocrinology 146 (2005) 3266-3276
14. Tenenbaum A., Fisman E.Z., Boyko V., Benderly M., Tanne D., Haim M., Matas Z., Motro M., and Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 166 (2006) 737-741
15. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470. This is an interesting review that focuses on the three PPAR isoforms (α, β/δ, γ) as therapeutic targets for the management of cardiovascular disease and the MS.
16. Lefebvre P., Chinetti G., Fruchart J.C., and Staels B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest 116 (2006) 571-580
17. Lee C.H., Olson P., and Evans R.M. Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology 144 (2003) 2201-2207
18. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45 (2006) 120-159
19. Marx N., Duez H., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
20. Zahradka P., Wright B., Fuerst M., Yurkova N., Molnar K., and Taylor C.G. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J Pharmacol Exp Ther 317 (2006) 651-659
21. Ye J.M., Doyle P.J., Iglesias M.A., Watson D.G., Cooney G.J., and Kraegen E.W. Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: comparison with PPAR-gamma activation. Diabetes 50 (2001) 411-417
22. Tsuchida A., Yamauchi T., Takekawa S., Hada Y., Ito Y., Maki T., and Kadowaki T. Peroxisome proliferator-activated receptor (PPAR){alpha} activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPAR{alpha}, PPAR{gamma}, and their combination. Diabetes 54 (2005) 3358-3370. In this study, the authors propose novel mechanisms by which activation of PPARα and/or PPARγ ameliorates insulin resistance, focusing on adipose tissue. Activation of PPARα suppresses inflammation and adipose hypertrophy in adipose tissue. Dual activation of PPARα and γ enhances the action of adiponectin by increasing both adiponectin and adiponectin receptor expression.
23. Carmona M.C., Louche K., Nibbelink M., Prunet B., Bross A., Desbazeille M., Dacquet C., Renard P., Casteilla L., and Penicaud L. Fenofibrate prevents rosiglitazone-induced body weight gain in ob/ob mice. Int J Obes (Lond) 29 (2005) 864-871
24. Brand C.L., Sturis J., Gotfredsen C.F., Fleckner J., Fledelius C., Hansen B.F., Andersen B., Ye J.M., Sauerberg P., and Wassermann K. Dual PPARalpha/gamma activation provides enhanced improvement of insulin sensitivity and glycemic control in ZDF rats. Am J Physiol Endocrinol Metab 284 (2003) E841-E854
25. Harrity T., Farrelly D., Tieman A., Chu C., Kunselman L., Gu L., Ponticiello R., Cap M., Qu F., Shao C., et al. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Diabetes 55 (2006) 240-248. Using genetically obese diabetic db/db mice as a model, the authors show that muraglitazar treatment results in an improved pancreatic β-cell function (lowering the insulin secretory demand on β-cells and preventing their apoptosis). They demonstrate the utility of db/db mice as a useful model for evaluating anti-diabetic and anti-dyslipidemic properties of novel PPAR activators.
26. Pickavance L.C., Brand C.L., Wassermann K., and Wilding J.P. The dual PPARalpha/gamma agonist, ragaglitazar, improves insulin sensitivity and metabolic profile equally with pioglitazone in diabetic and dietary obese ZDF rats. Br J Pharmacol 144 (2005) 308-316
27. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., Sorensen R.V., Larsen P.J., Cooney G.J., Wassermann K., et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am J Physiol Endocrinol Metab 284 (2003) E531-E540
28. Mamnoor P.K., Hegde P., Datla S.R., Damarla R.K., Rajagopalan R., and Chakrabarti R. Antihypertensive effect of ragaglitazar: a novel PPARalpha and gamma dual activator. Pharmacol Res 54 (2006) 129-135
29. Chakrabarti R., Misra P., Vikramadithyan R.K., Premkumar M., Hiriyan J., Datla S.R., Damarla R.K., Suresh J., and Rajagopalan R. Antidiabetic and hypolipidemic potential of DRF 2519-a dual activator of PPAR-alpha and PPAR-gamma. Eur J Pharmacol 491 (2004) 195-206
30. Verreth W., Ganame J., Mertens A., Bernar H., Herregods M.C., and Holvoet P. Peroxisome proliferator-activated receptor-{alpha},{gamma}-agonist improves insulin sensitivity and prevents loss of left ventricular function in obese, dyslipidemic mice. Arterioscler Thromb Vasc Biol 26 (2006) 922-928
31. Hegarty B.D., Furler S.M., Oakes N.D., Kraegen E.W., and Cooney G.J. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo - a study using the novel PPARalpha/gamma agonist tesaglitazar. Endocrinology 145 (2004) 3158-3164
32. Buse J.B., Rubin C.J., Frederich R., Viraswami-Appanna K., Lin K.C., Montoro R., Shockey G., and Davidson J.A. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes. Clin Ther 27 (2005) 1181-1195
33. Kendall D.M., Rubin C.J., Mohideen P., Ledeine J.M., Belder R., Gross J., Norwood P., O'Mahony M., Sall K., Sloan G., et al. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Diabetes Care 29 (2006) 1016-1023. This is the first study to compare the effects of muraglitazar and pioglitazone on glycemic control and lipid abnormalities in individuals withT2D who are inadequately controlled by metformin monotherapy.
34. Fagerberg B., Edwards S., Halmos T., Lopatynski J., Schuster H., Stender S., Stoa-Birketvedt G., Tonstad S., Halldorsdottir S., and Gause-Nilsson I. Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia 48 (2005) 1716-1725
35. Saad M.F., Greco S., Osei K., Lewin A.J., Edwards C., Nunez M., and Reinhardt R.R. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm. Diabetes Care 27 (2004) 1324-1329
36. Egerod F.L., Nielsen H.S., Iversen L., Thorup I., Storgaard T., and Oleksiewicz M.B. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 10 (2005) 295-309
37. Oleksiewicz M.B., Thorup I., Nielsen H.S., Andersen H.V., Hegelund A.C., Iversen L., Guldberg T.S., Brinck P.R., Sjogren I., Thinggaard U.K., et al. Generalized cellular hypertrophy is induced by a dual-acting PPAR agonist in rat urinary bladder urothelium in vivo. Toxicol Pathol 33 (2005) 552-560. This study examines the mechanisms behind the carcinogenic effects of ragaglitazar in rats, focusing on early (pre-cancerous) changes that occur in the bladder urothelium of the animals. This is the first study that reports a direct hypertrophic effect of a PPAR agonist. This effect is primary and occurs in the absence of changes in cell cycle distribution.
38. Cohen S.M. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 87 (2005) 322-327. This review addresses the issue of urothelial tumors induced by PPARγ and dual PPARα/γ agonists. It discusses the sex and species differences and the relevance to humans. The author proposes an indirect carcinogenic mechanism instead of a direct effect of PPARγ in the urothelium of rats, based on urine compositional changes.
39. Nissen S.E., Wolski K., and Topol E.J. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294 (2005) 2581-2586. From internet-posted documents on the FDA site, this analysis suggests that muraglitazar treatment is associated with an increased cardiovascular risk profile. Although there are important limitations to the analysis, such a study highlights the problem of safety issues with new compounds and proposes the requirement of long-term follow-up studies.
40. Doux J.D., Bazar K.A., Lee P.Y., and Yun A.J. Can chronic use of anti-inflammatory agents paradoxically promote chronic inflammation through compensatory host response?. Med Hypotheses 65 (2005) 389-391
41. Park S.Y., Cho Y.R., Finck B.N., Kim H.J., Higashimori T., Hong E.G., Lee M.K., Danton C., Deshmukh S., Cline G.W., et al. Cardiac-specific overexpression of peroxisome proliferator-activated receptor-alpha causes insulin resistance in heart and liver. Diabetes 54 (2005) 2514-2524
42. Umeno H., Watanabe A., Mori M., and Kobayashi T. AK109, a novel propionic acid derivative non-TZD dual PPARalpha/gamma agonist, has excellent safety margin and ADME profile [abstract]. American Diabetes Association Scientific Sessions (2005) 2172-PO
43. Reifel-Miller A., Otto K., Hawkins E., Barr R., Bensch W.R., Bull C., Dana S., Klausing K., Martin J.A., Rafaeloff-Phail R., et al. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 19 (2005) 1593-1605
44. Minoura H., Takeshita S., Yamamoto T., Mabuchi M., Hirosumi J., Takakura S., Kawamura I., Seki J., Manda T., Ita M., et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol 519 (2005) 182-190
45. Wright H.M., Clish C.B., Mikami T., Hauser S., Yanagi K., Hiramatsu R., Serhan C.N., and Spiegelman B.M. A synthetic antagonist for the peroxisome proliferator-activated receptor gamma inhibits adipocyte differentiation. J Biol Chem 275 (2000) 1873-1877
46. Mukherjee R., Hoener P.A., Jow L., Bilakovics J., Klausing K., Mais D.E., Faulkner A., Croston G.E., and Paterniti Jr. J.R. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14 (2000) 1425-1433
47. Rieusset J., Touri F., Michalik L., Escher P., Desvergne B., Niesor E., and Wahli W. A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16 (2002) 2628-2644
48. Decochez K., Rippley R.K., Miller J.L., De Smet M., Yan K.X., Matthijs Z., Riffel K.A., Song H., Zhu H., Maynor H.O., et al. A dual PPAR alpha/gamma agonist increases adiponectin and improves plasma lipid profiles in healthy subjects. Drugs R D 7 (2006) 99-110